INSIGHTS ON UPSTREAM MANUFACTURING

• Rapid Selection Of High-Performance CHO Basal And Feed Media

  A CHO-S bispecific antibody program needed a better basal and feed media combination. Learn how the screening of 180 conditions in 12 weeks identified one that delivered 38% higher titers.

• Advancing Cell Culture Strategies To Accelerate Biologics Development

  Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks, variability, and risks in transitioning from discovery to manufacturing.

• Aligning Upstream And Downstream Development (Part 2)

  In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their discussion about how upstream and downstream development teams can work together to accelerate timelines and reduce risk and bottlenecks in process development.

• Top 5 Barriers To Scalable ncAA Conjugation And What's Finally Changing

  Examine data from an anti-GPCR VHH program that shows how ncAA conjugation barriers, like yield loss, toxicity, incomplete incorporation, can be overcome at scale.

• Solving The DNA Knock-In Problem

  5/1/2026

  An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.

• Expanding The Capabilities Of Targeted Integration

  5/1/2026

  See the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.

• Redefining Cell Line Development For Next-Generation Biologics

  4/30/2026

  A transposon‑enabled cell line development strategy streamlines upstream optimization, shortening timelines while improving consistency, yield, and quality across recombinant protein modalities.

• From DNA To IND In As Little As 6 Months

  4/27/2026

  Discover how an integrated, platform-driven CMC approach can accelerate your antibody program from DNA to IND in as little as six months while reducing risk and maintaining quality and regulatory alignment.